Glucagon-like Peptide-1(7–36) Amide Stimulates  Surfactant Secretion in Human Type II Pneumocytes

Vara, Elena; Arias-Dı́az, Javier; Garcı́a, Cruz; Balibrea, J.L.; Blázquez, Enrique

doi:10.1164/ajrccm.163.4.9912132

Cited by 54 publications

(47 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Glucagon-like peptide 1, known to stimulate insulin secretion, also stimulates surfactant secretion in human type II pneumocytes (20). In a rat model of diabetic pregnancy, insulin treatment resulted in a substantial increase in SP-A mRNA levels over those from untreated diabetic pregnancies (21).…”

Section: Ferná Ndez-real and Associatesmentioning

confidence: 99%

Circulating Surfactant Protein A (SP-A), a Marker of Lung Injury, Is Associated With Insulin Resistance

et al. 2008

View full text Add to dashboard Cite

OBJECTIVES -Impaired lung function and inflammation have both attracted interest as potentially novel risk factors for glucose intolerance, insulin resistance, and type 2 diabetes. We hypothesized that circulating levels of surfactant protein (SP)-A, which reflects interstitial lung injury, could be associated with altered glucose tolerance and insulin resistance.RESEARCH DESIGN AND METHODS -Circulating SP-A concentration and metabolic variables (including insulin sensitivity by minimal model method, n ϭ 89) were measured in 164 nonsmoking men.RESULTS -Circulating SP-A concentration was significantly higher among patients with glucose intolerance and type 2 diabetes than in subjects with normal glucose tolerance, even after adjustment for BMI, age, and smoking status (ex/never). The most significant differences were found in overweight and obese subjects with altered glucose tolerance (n ϭ 59) who showed significantly increased serum SP-A concentrations (by a mean of 24%) compared with obese subjects with normal glucose tolerance (n ϭ 58) (log SP-A 1.54 Ϯ 0.13 vs. 1.44 Ϯ 0.13; P Ͻ 0.0001). Insulin sensitivity (P ϭ 0.003) contributed independently to 22% of SP-A variance among all subjects. In subjects with altered glucose tolerance, insulin sensitivity (P ϭ 0.01) and fasting triglycerides (P ϭ 0.02) contributed to 37% of SP-A variance. Controlling for serum creatinine or C-reactive protein in these models did not significantly change the results.CONCLUSIONS -Lung-derived SP-A protein was associated with altered glucose tolerance and insulin resistance in 164 nonsmoking men. Diabetes Care 31:958-963, 2008

show abstract

Section: Ferná Ndez-real and Associatesmentioning

confidence: 99%

Circulating Surfactant Protein A (SP-A), a Marker of Lung Injury, Is Associated With Insulin Resistance

et al. 2008

View full text Add to dashboard Cite

show abstract

“…However, there are also promising preclinical results in the reduction of infarct volume in ischemic heart disease [21]. Adult rat and human type 2 pneumocytes show increased surfactant protein secretion in the presence of GLP-1 (7-36) amide [22,23]. Transplacental administration of GLP-1 in a teratogenic model (nitrofen rat) of CDH showed an improvement in fetal lung-to-body-weight ratio (LBWR) and survival [24].…”

Section: Introductionmentioning

confidence: 99%

The Effect of Transplacental Administration of Glucagon-Like Peptide-1 on Fetal Lung Development in the Rabbit Model of Congenital Diaphragmatic Hernia

et al. 2015

View full text Add to dashboard Cite

Objective: Glucagon-like peptide-1 (GLP-1) increases surfactant protein expression in type 2 pneumocytes. Herein, we determine if transplacental GLP-1 treatment accelerates lung growth in the fetal rabbit model of congenital diaphragmatic hernia (DH). Methods: Time-mated does had an induction of DH on day 23 followed by daily GLP-1 or placebo injection until term. At that time, the does were weighed, fetal blood was obtained for GLP-1 assay, and the lungs were dissected. Fetal outcome measures were lung-to-body-weight ratio (LBWR), morphometry, and Ki67 and surfactant protein B (SPB) expression. Results: Maternal weight loss in the GLP-1 group was 7.1%. Fetal survival was lower in GLP-1 fetuses compared to placebo controls (27/85, 32% vs. 35/57, 61%; p < 0.05). Fetal GLP-1 levels were increased 3.6-fold. The LBWR of GLP-1 DH fetuses fell within the range of DH placebo fetuses (1.166 ± 0.207% vs. 1.312 ± 0.418%), being significantly lower than that of placebo-exposed unoperated fetuses (2.280 ± 0.522%; p < 0.001). GLP-1 did not improve airway morphometry. GLP-1 DH lungs had a reduced adventitial and medial thickness within the range of controls, and lesser muscularization of vessels measuring 30-60 µm. There were no differences in Ki67 and SPB expression. Conclusion: GLP-1 at this dosage improves peripheric pulmonary vessel morphology in intra-acinar vessels with no effect on airway morphometry but with significant maternal and fetal side effects. Thus, it is an unlikely medical strategy.

show abstract

“…Furthermore, current knowledge of the GLP-1 receptor expression in normal human tissues is very incomplete as well. It is based largely on receptor messenger RNA (mRNA) investigations in wholeorgan preparations (19)(20)(21), but very little information is available on the receptor protein expression, the exact tissue localization of the receptor, and the receptor density levels in human organs. Therefore, we performed a study to assess the GLP-1 receptor protein expression, first, in a broad spectrum of human tumors, and, second, in normal human tissues from common sites of tumor origin and metastasis using in vitro receptor autoradiography.…”

mentioning

confidence: 99%

GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting

Körner

Stöckli²,

Waser³

et al. 2007

Journal of Nuclear Medicine

406

303

View full text Add to dashboard Cite

Peptide hormone receptors overexpressed in human tumors, such as somatostatin receptors, can be used for in vivo targeting for diagnostic and therapeutic purposes. A novel promising candidate in this field is the GLP-1 receptor, which was recently shown to be massively overexpressed in gut and lung neuroendocrine tumors-in particular, in insulinomas. Anticipating a major development of GLP-1 receptor targeting in nuclear medicine, our aim was to evaluate in vitro the GLP-1 receptor expression in a large variety of other tumors and to compare it with that in nonneoplastic tissues. Methods: The GLP-1 receptor protein expression was qualitatively and quantitatively investigated in a broad spectrum of human tumors (n 5 419) and nonneoplastic human tissues (n 5 209) with receptor autoradiography using 125 I-GLP-1(7-36)amide. Pharmacologic competition experiments were performed to provide proof of specificity of the procedure. Results: GLP-1 receptors were expressed in various endocrine tumors, with particularly high amounts in pheochromocytomas, as well as in brain tumors and embryonic tumors but not in carcinomas or lymphomas. In nonneoplastic tissues, GLP-1 receptors were present in generally low amounts in specific tissue compartments of several organs-namely, pancreas, intestine, lung, kidney, breast, and brain; no receptors were identified in lymph nodes, spleen, liver, or the adrenal gland. The rank order of potencies for receptor binding-namely, GLP-1(7-36)amide 5 exendin-4 GLP-2 5 glucagon(1-29)-provided proof of specific GLP-1 receptor identification. Conclusion: The GLP-1 receptors may represent a novel molecular target for in vivo scintigraphy and targeted radiotherapy for a variety of GLP-1 receptor-expressing tumors. For GLP-1 receptor scintigraphy, a low-background signal can be expected, on the basis of the low receptor expression in the normal tissues surrounding tumors. G protein-coupled peptide hormone receptors play an increasing role in cancer medicine. This role is based primarily on the peptide receptor overexpression on tumor cells, which allows specific receptor-targeted scintigraphic tumor imaging and tumor therapy with radiolabeled peptide analogs (1). The somatostatin receptors were the first peptide receptors identified for these purposes, and somatostatin receptor targeting has now become an integral part of the routine management of patients with gastroenteropancreatic neuroendocrine tumors. Somatostatin receptor scintigraphy (OctreoScan [ 111 In-pentetreotide]; Mallinckrodt, Inc.) detects these tumors with extremely high sensitivity and specificity (2). Moreover, recent results from clinical studies performing somatostatin receptor radionuclide therapy of these tumors are very promising (3,4).Prompted by the success of somatostatin receptor targeting, we have evaluated the overexpression of other peptide receptor families in tumors in vitro (1), with the aim, eventually, of being able to target in vivo a larger spectrum of tumors or individual tumors more efficiently with multiple pepti...

show abstract

Glucagon-like Peptide-1(7–36) Amide Stimulates Surfactant Secretion in Human Type II Pneumocytes

Cited by 54 publications

References 34 publications

Circulating Surfactant Protein A (SP-A), a Marker of Lung Injury, Is Associated With Insulin Resistance

Circulating Surfactant Protein A (SP-A), a Marker of Lung Injury, Is Associated With Insulin Resistance

The Effect of Transplacental Administration of Glucagon-Like Peptide-1 on Fetal Lung Development in the Rabbit Model of Congenital Diaphragmatic Hernia

GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting

Contact Info

Product

Resources

About